Experts urge FDA to require credentials for psychedelic therapy providers

At a recent public hearing, mental health experts called on the FDA to adopt safety measures as it pushes to speed up psychedelic therapy development.

The experts specifically recommended that providers of psychedelic treatments be required to hold verified credentials, arguing that this would protect patients and ensure quality care.

They emphasized that credential verification should be part of the agency's broader framework for overseeing clinical trials and post‑approval use of these emerging therapies.

The FDA has not yet announced a formal policy, but the hearing highlights growing regulatory scrutiny as the market for psychedelic medicines expands.